Cover Image

The EBMT/EHA CAR-T Cell Handbook.

Bibliographic Details
Main Author: Kröger, Nicolaus.
Other Authors: Gribben, John., Chabannon, Christian., Yakoub-Agha, Ibrahim., Einsele, Hermann.
Format: eBook
Language:English
Published: Cham : Springer International Publishing AG, 2022.
Edition:1st ed.
Subjects:
Electronic books.
Online Access:Click to View
LEADER 08758nam a22004573i 4500
001 EBC6884928
003 MiAaPQ
005 20231204023221.0
006 m o d |
007 cr cnu||||||||
008 231204s2022 xx o ||||0 eng d
020 |a 9783030943530  |q (electronic bk.) 
020 |z 9783030943523 
035 |a (MiAaPQ)EBC6884928 
035 |a (Au-PeEL)EBL6884928 
035 |a (OCoLC)1299386533 
040 |a MiAaPQ  |b eng  |e rda  |e pn  |c MiAaPQ  |d MiAaPQ 
050 4 |a RT1-120 
100 1 |a Kröger, Nicolaus. 
245 1 4 |a The EBMT/EHA CAR-T Cell Handbook. 
250 |a 1st ed. 
264 1 |a Cham :  |b Springer International Publishing AG,  |c 2022. 
264 4 |c {copy}2022. 
300 |a 1 online resource (221 pages) 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
505 0 |a Intro -- Preface -- Contents -- Part I: The Science Behind CAR-T Cells -- 1: Structure of and Signalling Through Chimeric Antigen Receptor -- References -- 2: Genetic Engineering of Autologous or Allogeneic Immune Effector Cells -- References -- 3: What Defines a Good Tumour Antigen? -- Tumour-Specific Antigens (TSAs) -- Multiple Tumour Antigens Resulting in a 'Tumour-Specific Phenotype' -- Lineage-Specific and Differentiation Antigens -- Lineage-Specific Polymorphic/Heterogeneic Antigens -- References -- 4: Tumour Escape from CAR-T Cells -- Immune Escape and CAR-T Cell Resistance Related to Antigen Loss -- Immune Dysfunction and Exhaustion of CAR-T Cells -- Microenvironment-Mediated Tumour Resistance to CAR-T Cells -- References -- 5: CART Initiatives in Europe -- References -- Part II: Manufacturing CAR-T Cells: The Supply Chain -- 6: Providing the Starting Material to the Manufacturer of an Approved and Commercially Available Autologous CAR-T Cell Treatment -- Introduction -- References -- 7: Receiving, Handling, Storage, Thawing, Distribution, and Administration of CAR-T Cells Shipped from the Manufacturing Facility -- Definition -- Administration -- Patients Treated with CAR-T Cells: New Missions for the Hospital Pharmacist -- References -- 8: Point-of-Care Production of CAR-T Cells -- GMP Vector Production -- Manufacturing CAR-T Cells -- References -- 9: Off-the-Shelf Allogeneic CAR-T Cells or Other Immune Effector Cells -- Strategies to Avoid Graft Versus Host Disease (GvHD) -- Genome Edited αβTCR-Deleted T Cells -- Virus-Specific T (VST) Cells -- Alternative Immune Effector Cells -- Strategies to Avoid Host-Mediated Rejection of Allogeneic Immune Cells -- Resistance to Lymphodepletion and Immunosuppression -- Removal of HLA for Evading Host Immunity -- Manufacturing Aspects of 'Off-the-Shelf' CARs -- References. 
505 8 |a Part III: Clinical Indications for CAR-T Cells -- 10: Paediatric Acute Lymphoblastic Leukaemia (ALL) -- References -- 11: Adult Acute Lymphoblastic Leukaemia -- CAR-T Cell Therapy for Adult ALL -- Consolidation After CAR-T Cell Therapy -- Relapse After CAR-T Cell Therapy -- References -- 12: Diffuse Large B Cell Lymphoma and Primary Mediastinal Lymphoma -- Patient Population to Consider: Lymphoma-Specific Aspects -- Treatment History -- Remission Status and Tumour Bulk Prior to CAR-T Cell Infusion -- Histology -- Patient Population to Consider: Patient-Specific Aspects -- Alternative Treatments -- References -- 13: Mantle Cell Lymphoma -- Clinical Indications for CAR-T Cells -- Critical Evaluation -- References -- 14: Chronic Lymphocytic Leukaemia -- Clinical Development of CAR-T Cells for CLL -- Current Indications for CAR-T Cells in the Treatment Landscape of CLL -- Prospective Studies of Autologous Anti-CD19 CAR-T Cell Therapy for CLL -- References -- 15: Indolent Lymphomas -- References -- 16: Multiple Myeloma -- References -- 17: Developments in Other Haematological Malignancies: Other Lymphoid Malignancies -- Target Antigens -- CAR-T Development in T Cell Malignancies -- Bibliography -- 18: Myeloid Malignancies -- Single or Dual Antigen Targeting? -- Molecular Engineering of the Chimeric Receptor and Alternative Cell Sources -- References -- 19: Developments in Solid Tumours -- References -- Part IV: Clinical Management of Patients Treated with CAR-T Cells -- 20: Bridging Chemotherapy: Adult Acute Lymphoblastic Leukaemia -- References -- Further Reading -- 21: Bridging to CAR-T Cells in Children, Adolescents, and Young Adults with ALL -- The Importance of the Bridge -- Is There a Place for Immunotherapy? -- References -- 22: Bridging Chemotherapy: Relapsed/Refractory Aggressive B-Cell Lymphoma. 
505 8 |a To Bridge or Not to Bridge in Relapsed and Refractory (R/R) Aggressive B-Cell Lymphoma? -- Which Bridging Therapy? -- Response Rate to Bridging Therapy and Subsequent CAR-T Cell Therapy -- References -- 23: Bridging Chemotherapy: Follicular Lymphoma, Mantle Cell Lymphoma, and CLL -- References -- 24: Bridging Chemotherapy: Multiple Myeloma -- Should All MM Patients Receive Bridging Therapy? -- Timeframe to Use Bridging Treatments -- Choice of Treatment -- References -- 25: Lymphodepleting Conditioning Regimens -- References -- 26: Management of Cytokine Release Syndrome (CRS) and HLH -- Cytokine Release Syndrome (CRS) -- Definition and Occurrence -- Diagnosis -- Clinical Symptoms, Laboratory Diagnosis, Differential Diagnosis, and Predictive Factors -- Management -- Anti-Cytokines -- Steroids -- Antibiotics -- sHLH/MAS -- References -- 27: Management of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) -- Further Reading -- 28: Management of Hypogammaglobulinaemia and B-Cell Aplasia -- References -- 29: Management of Myelotoxicity (Aplasia) and Infectious Complications -- References -- 30: Management of Other Toxicities -- Considerations for Patients Undergoing CAR-T Cell Therapy -- References -- 31: ICU -- References -- 32: Post-CAR-T Cell Therapy (Consolidation and Relapse): Acute Lymphoblastic Leukaemia -- Management of Relapsed B-ALL After CD19 CAR-T Cell Therapy -- CD19-Positive Disease After CD19 CAR-T Cell Therapy -- CD19-Negative Disease After CD19 CAR-T Cell Therapy -- References -- 33: Post-CAR-T Cell Therapy (Consolidation and Relapse): Lymphoma -- References -- 34: Post-CAR-T Cell Therapy (Consolidation and Relapse): Multiple Myeloma -- References -- 35: Immune Monitoring -- Molecular Monitoring of CAR-T Cells via Digital PCR (dPCR) -- Flow Cytometry Monitoring of CAR-T Cells. 
505 8 |a Monitoring of Additional Immune Parameters (Non-CAR-T, B, and NK Cells and Cytokines) -- References -- 36: Long-Term Follow-Up and Late Effects -- Follow-Up and Programmes -- Post-authorisation Safety Surveillance (PASS) -- JACIE -- References -- Part V: Access to CAR-T Cells -- 37: The Regulatory Framework for CAR-T Cells in Europe: Current Status and Foreseeable Changes AND Centre Qualification by Competent Authorities and Manufacturers -- Current Framework -- Hospital Exemption -- Role of Academia -- Health Technology Assessment -- Future Focus -- Centre Qualification by Competent Authorities and Manufacturers -- Shared Goals -- Centre Assessment -- Centre Auditing -- Centre Training -- References -- 38: How Can Accreditation Bodies, Such as JACIE or FACT, Support Centres in Getting Qualified? -- References -- 39: Educational Needs for Physicians -- References -- 40: Education Needs for Nurses in Adult and Paediatric Units -- Apheresis and Cell Collection -- Cell Infusion -- Patient Monitoring -- Toxicity Management -- Discharge -- Long-Term Follow Up -- Paediatric Considerations -- References -- 41: Role of Pharmacists -- References -- 42: Educational Needs for Cell Processing Facility Personnel -- 43: GoCART -- 44: Patient Referral -- References -- 45: Treatment Coverage and Reimbursement -- 46: The Value of CAR-T-cell Immunotherapy in Cancer -- References -- 47: What do Patients Want? The Importance of Patient-reported Outcomes -- References. 
588 |a Description based on publisher supplied metadata and other sources. 
590 |a Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2023. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries.  
655 4 |a Electronic books. 
700 1 |a Gribben, John. 
700 1 |a Chabannon, Christian. 
700 1 |a Yakoub-Agha, Ibrahim. 
700 1 |a Einsele, Hermann. 
776 0 8 |i Print version:  |a Kröger, Nicolaus  |t The EBMT/EHA CAR-T Cell Handbook  |d Cham : Springer International Publishing AG,c2022  |z 9783030943523 
797 2 |a ProQuest (Firm) 
856 4 0 |u https://ebookcentral.proquest.com/lib/matrademy/detail.action?docID=6884928  |z Click to View 

Similar Items